Advances in Chronic Kidney Disease
Volume 16, Issue 3 , Pages 173-178 , May 2009

Cardiovascular Effects of Home Intensive Hemodialysis

  • Christopher T. Chan, MD, FRCPC

      Affiliations

    • Corresponding Author InformationAddress correspondence to Christopher T Chan, Toronto General Hospital, University Health Network, 200 Elizabeth Street, 8N Room 842, Toronto, Ontario M5G 2C4, Canada.

References 

  1. Collins AJ. Cardiovascular mortality in end-stage renal disease. Am J Med Sci. 2003;325:163–167
  2. DePalma JR, Pecker EA, Gordon A, et al. A new compact automatic home hemodialysis system. Trans Am Soc Artif Intern Organs. 1968;14:152–159
  3. Uldall R, Ouwendyk M, Francoeur R, et al. Slow nocturnal home hemodialysis at the Wellesley Hospital. Adv Ren Replace Ther. 1996;3:133–136
  4. Kraus M, Burkart J, Hegeman R, et al. A comparison of center-based vs. home-based daily hemodialysis for patients with end-stage renal disease. Hemodial Int. 2007;11:468–477
  5. Lindner A, Charra B, Sherrard DJ, et al. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med. 1974;290:697–701
  6. London GM. Cardiovascular disease in chronic renal failure: Pathophysiologic aspects. Semin Dial. 2003;16:85–94
  7. Zoccali C, Mallamaci F, Tripepi G. Traditional and emerging cardiovascular risk factors in end-stage renal disease. Kidney Int Suppl. 2003;105–110
  8. Hruska KA, Mathew S, Lund R, et al. Hyperphosphatemia of chronic kidney disease. Kidney Int. 2008;74:148–157
  9. Amann K, Ritz E, Wiest G, et al. A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. J Am Soc Nephrol. 1994;4:1814–1819
  10. Foley RN. Clinical epidemiology of cardiac disease in dialysis patients: Left ventricular hypertrophy, ischemic heart disease, and cardiac failure. Semin Dial. 2003;16:111–117
  11. Szmitko PE, Fedak PW, Weisel RD, et al. Endothelial progenitor cells: New hope for a broken heart. Circulation. 2003;107:3093–3100
  12. Tongers J, Losordo DW. Frontiers in nephrology: The evolving therapeutic applications of endothelial progenitor cells. J Am Soc Nephrol. 2007;18:2843–2852
  13. London GM. Vascular disease and atherosclerosis in uremia. Blood Purification. 2001;19:139–142
  14. Woods JD, Port FK, Orzol S, et al. Clinical and biochemical correlates of starting “daily” hemodialysis. Kidney Int. 1999;55:2467–2476
  15. Fagugli RM, Reboldi G, Quintaliani G, et al. Short daily hemodialysis: Blood pressure control and left ventricular mass reduction in hypertensive hemodialysis patients. Am J Kidney Dis. 2001;38:371–376
  16. Chan CT, Floras JS, Miller JA, et al. Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis. Kidney Int. 2002;61:2235–2239
  17. Nesrallah G, Suri R, Moist L, et al. Volume control and blood pressure management in patients undergoing quotidian hemodialysis. Am J Kidney Dis. 2003;42:13–17
  18. Chan CT, Harvey PJ, Picton P, et al. Short-term blood pressure, noradrenergic, and vascular effects of nocturnal home hemodialysis. Hypertension. 2003;42:925–931
  19. Foley RN, Parfrey PS, Harnett JD, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney International. 1995;47:186–192
  20. Culleton BF, Walsh M, Klarenbach SW, et al. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: A randomized controlled trial. JAMA. 2007;298:1291–1299
  21. Suri RS, Garg AX, Chertow GM, et al. Frequent Hemodialysis Network (FHN) randomized trials: Study design. Kidney Int. 2007;71:349–359
  22. Raggi P, Kleerekoper M. Contribution of bone and mineral abnormalities to cardiovascular disease in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2008;3:836–843
  23. Chan CT, Jain V, Picton P, et al. Nocturnal hemodialysis increases arterial baroreflex sensitivity and compliance and normalizes blood pressure of hypertensive patients with end-stage renal disease. Kidney Int. 2005;68:338–344
  24. Chan CT, Shen XS, Picton P, et al. Nocturnal home hemodialysis improves baroreflex effectiveness index of end-stage renal disease patients. J Hypertens. 2008;26:1795–1800
  25. Suki WN. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients: Results of a randomized clinical trial. J Ren Nutr. 2008;18:91–98
  26. Manns B, Klarenbach S, Lee H, et al. Economic evaluation of sevelamer in patients with end-stage renal disease. Nephrol Dial Transplant. 2007;22:2867–2878
  27. Tonelli M, Sacks F, Pfeffer M, et al. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation. 2005;112:2627–2633
  28. Spalding EM, Chamney PW, Farrington K. Phosphate kinetics during hemodialysis: Evidence for biphasic regulation. Kidney Int. 2002;61:655–667
  29. Kim SJ, Goldstein M, Szabo T, et al. Resolution of massive uremic tumoral calcinosis with daily nocturnal home hemodialysis. Am J Kidney Dis. 2003;41:E12
  30. Yuen D, Pierratos A, Richardson RM, et al. The natural history of coronary calcification progression in a cohort of nocturnal haemodialysis patients. Nephrol Dial Transplant. 2006;21:1407–1412
  31. Fishbane S, Besarab A. Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets. Clin J Am Soc Nephrol. 2007;2:1274–1282
  32. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584–590
  33. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–2098
  34. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–2084
  35. Ting GO, Kjellstrand C, Freitas T, et al. Long-term study of high-comorbidity ESRD patients converted from conventional to short daily hemodialysis. Am J Kidney Dis. 2003;42:1020–1035
  36. Schwartz DI, Pierratos A, Richardson RM, et al. Impact of nocturnal home hemodialysis on anemia management in patients with end-stage renal disease. Clin Nephrol. 2005;63:202–208
  37. Chan CT, Li SH, Verma S. Nocturnal hemodialysis is associated with restoration of impaired endothelial progenitor cell biology in end-stage renal disease. Am J Physiol Renal Physiol. 2005;289:F679–684
  38. Chan CT, Gold WL. Intramedullary abscess of the spinal cord in the antibiotic era: Clinical features, microbial etiologies, trends in pathogenesis, and outcomes. Clin Infect Dis. 1998;27:619–626
  39. Ayus JC, Mizani MR, Achinger SG, et al. Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: A prospective, controlled study. J Am Soc Nephrol. 2005;16:2778–2788

PII: S1548-5595(09)00047-0

doi: 10.1053/j.ackd.2009.02.003

Advances in Chronic Kidney Disease
Volume 16, Issue 3 , Pages 173-178 , May 2009

Article Tools